CUE — Cue Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1645460 ·
Last close
$31.41
Market Cap
$228.18M
52W High
$45.50
52W Low
$4.98
ADV30
346,937
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 7,877,000 | — | -87,695,000 | -153,067,000 | 30,707,000 | 17,392,000 | 28,397,000 |
| Mar 2026 | 5,686,000 | — | -5,363,000 | -5,178,000 | 30,877,000 | 16,379,000 | 9,269,000 |
| Dec 2025 | 21,942,000 | — | 1,958,000 | 1,585,000 | 42,212,000 | 27,136,000 | 15,780,000 |
| Sep 2025 | 2,149,000 | — | -7,544,000 | -7,448,000 | 31,644,000 | 11,701,000 | 18,398,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,457,000
Investing CF
$104,000
Financing CF
$27,597,000
CapEx
$-300,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.58
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-373,644,000
Inventory
—
Receivables
$7,250,000
ST Investments
$6,971,000
EBIT TTM
$-18,848,000
Pretax Income TTM
$-19,023,000
Interest Exp TTM
$175,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$37,655,000
EBITDA
$-97,284,000
Free Cash Flow
$-33,425,750
Enterprise Value
$194,442,256
Total Cash
$17,414,000
Total Debt
$3,077,000
Shares Out
7,264,414
Trailing EPS
$-29.46
Book Value
$0.44
ROE
-1603.5%
ROA
-172.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 27,466,000 | -26,521,000 | -26,602,000 | 42,212,000 | 15,780,000 | 26,432,000 | -21,687,000 |
| Dec 2024 | 9,287,000 | -41,593,000 | -40,674,000 | 32,191,000 | 14,692,000 | 17,499,000 | -36,329,000 |
| Dec 2023 | 5,490,000 | -51,992,000 | -50,733,000 | 61,530,000 | 24,445,000 | 37,085,000 | -39,961,000 |
| Dec 2022 | 1,245,000 | -53,502,000 | -53,010,000 | 91,283,000 | 25,601,000 | 65,682,000 | -41,806,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NATR | NATURES SUNSHINE PRODUCTS INC | $227.33M | $12.92 | — |
| KROS | Keros Therapeutics, Inc. | $230.39M | $11.62 | — |
| RNAC | Cartesian Therapeutics, Inc. | $224.19M | $7.41 | — |
| PRQR | ProQR Therapeutics N.V. | $232.85M | $1.65 | — |
| SION | Sionna Therapeutics, Inc. | $236.14M | $5.23 | — |
News headlines (Yahoo Finance, 1h cache)
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
2026-09-28 09:02 · Yahoo
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
2026-09-26 03:45 · Yahoo
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
2026-09-22 14:17 · Yahoo
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
2026-09-21 10:55 · Yahoo
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
2026-09-20 10:00 · Yahoo
Cue Biopharma Announces $50.0 Million Private Placement
2026-07-10 01:40 · Yahoo
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-21 20:05 · Yahoo
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
2026-05-14 20:07 · Yahoo
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 23:07 · Yahoo
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
2026-04-30 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.